Willis Towers Watson Public Limited Company (WTW)
POSITIVE基本面
72
价格
$347.80
市值
$31.76B
第一部分 · 这家公司值多少
概览
WTW advises companies on two related but distinct problems: how to run and pay for employee benefits, retirement plans and workforce programs (Health, Wealth & Career), and how to identify, price and place their insurance risk with underwriters (Risk & Broking). It does not take on insurance risk itself — it earns fees and commissions for the advice and for arranging coverage, sitting as an intermediary between corporate clients and the insurers, reinsurers and pension providers that actually carry the risk.
盈利方式
Risk & Broking earns commissions and fees typically set as a percentage of the insurance premium it places, so revenue rises when insurance prices are rising (a "hard market") even if the volume of risk placed stays flat. Health, Wealth & Career charges advisory fees for benefits and retirement consulting, plus asset-based fees on the retirement assets it advises on. Neither segment underwrites risk on its own balance sheet, which keeps the business fee-driven rather than capital-intensive.
分部营收
Consulting and administration for employee health, retirement and benefits programs, plus advice on workforce and career strategy.
Brokerage placing corporate and specialty insurance and reinsurance with underwriters, plus related risk consulting and technology.
护城河
转换成本 · 狭窄Once WTW is embedded as a company's broker of record or benefits administrator, switching means re-underwriting relationships, re-running procurement and retraining internal teams, so clients tend to renew rather than re-tender every year. Aon, Marsh McLennan and Gallagher offer the same lock-in to their own clients, so the advantage is about retaining existing accounts more than winning new ones on merit alone.
需求驱动因素
中度周期性Companies need employee benefits and insurance coverage in good times and bad, which makes underlying demand fairly steady. But Risk & Broking's revenue is also shaped by the insurance pricing cycle — commissions swell when premiums are rising and can stall when a soft market sets in — so results move with insurance pricing even when the amount of risk being placed does not change much.
主要风险
- Legacy pension liabilities — The company carries material unfunded and underfunded pension obligations, and moves in interest rates, investment returns or inflation can materially affect the level of those liabilities.
- Professional liability and errors claims — Giving advice on risk, benefits and insurance placement exposes WTW to errors-and-omissions claims from clients when outcomes go wrong, regardless of whether the advice was reasonable at the time.
- Cybersecurity threats — WTW and its vendors regularly face cybersecurity incidents, and the company acknowledges these risks are evolving, including threats amplified by generative AI, with no guarantee a future incident stays immaterial.
- Sensitivity to the insurance pricing cycle — Risk & Broking commissions are tied to insurance premium levels; a prolonged soft market where premiums fall would reduce revenue even if the amount of risk placed stays the same.
看多理由
Buyers argue that being one of a handful of global brokers gives WTW pricing power and scale advantages smaller rivals cannot match, that switching costs keep client relationships sticky, and that a hardening insurance market lifts commission revenue without WTW having to do anything differently.
看空理由
Sellers fear that a softening insurance cycle would compress commission revenue across the board, that legacy pension liabilities remain a source of unpredictable charges, and that professional liability exposure from decades of advice is a risk that never fully goes away.
Written by the editors, published on 2026年8月18日
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
资产负债表与流动性
营收
$9.91B
最近12个月(截至2026/6/30)
净利润
$1.56B
最近12个月(截至2026/6/30)
自由现金流
$1.55B
股东权益合计
$7.98B
负债合计
$21.48B
流动比率
1.10
利息覆盖率
7.85
债务/EBITDA
2.52
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$428.17
当前价格
$347.80
安全边际
+18.8%
公允价值区间
$278.31 - $578.02
估算方法
估值指标
市盈率(P/E)
21.73
ROE
20.1%
市净率(P/B)
4.24
P/FCF
19.29
毛利率
-
ROIC
11.6%
盈利能力雷达图
Value Creation (Economic Moat)
ROIC
11.6%
WACC
7.1%
ROIC − WACC
+4.5 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
基本面分析标准
通过(20)
- EPS shows upward trend
- EPS CAGR 12.99%
- Price CAGR 10.83%
- ROIC 11.6%
- P/FCF 19.29
- Debt/Equity ratio
- Operating Margin 22.7%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 20.0%
- Analyst Consensus 71% Buy
- PEG Ratio 1.25
- Earnings Quality (OCF/NI) 1.23
- Share Dilution -3.3%
- Net Margin Trend 15.8% vs 1.4%
- Piotroski F-Score 6/9
未通过(6)
- P/B Ratio 4.24
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue Growth 5Y 2.4%
- Earnings Surprise avg 1.9%
不可用(2)
- Gross Margin NaN%
- Dividend Payout NaN%
Piotroski F-评分
信号混杂:部分领域需关注
盈利质量
高质量:盈利有现金流支撑
股权稀释
正在回购股份,对股东友好
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Mr. Carl Aaron Hess CERA, F.S.A. | CEO & Director | 63 |
| Mr. Andrew Jay Krasner | CFO & Co-head of Corporate Development | 48 |
| Mr. Matthew S. Furman | General Counsel | 55 |
| Ms. Julie Jarecke Gebauer | President of Health, Wealth & Career | 64 |
| Ms. Lucy Clarke | President of Risk & Broking | 58 |
| Ms. Alexis Faber | Chief Operating Officer | 47 |
| Mr. Joseph Stephen Kurpis | Principal Accounting Officer & Controller | 65 |
| Mr. Eric Arnaldo Latalladi | Global Head of Technology | - |
| Ms. Claudia De La Hoz | Head of Investor Relations | - |
| Ms. Kristy D. Banas | Chief Human Resources Officer and Head of Marketing & Communication | 53 |
审计风险
2
董事会风险
2
薪酬风险
2
股东权利风险
6
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。
Latest News
Recent headlines for WTW, sourced from Markets Gazette.
- 6/4/2026POSITIVEWeight Watchers Broadens GLP-1 Reach As Eli Lilly Pursues New Kidney Disease Therapies
Weight Watchers is expanding its reach for GLP-1 medications through a new partnership with LillyDirect, a platform by Eli Lilly and Company. This collaboration aims to provide Weight Watchers members with enhanced access to GLP-1 treatments, potentially boosting membership and revenue. Concurrently, Eli Lilly is advancing its kidney disease pipeline with a significant research agreement with Ascidian, valued up to $1.9 billion. While the Ascidian deal highlights Lilly's broader therapeutic ambitions, the Weight Watchers partnership directly impacts its core business, suggesting a positive outlook for the company's strategy in leveraging pharmaceutical advancements.
- 6/2/2026POSITIVEInsurance giant WTW moves into crypto asset recovery with Redefind buy
Global insurance broker WTW has entered the digital asset space by acquiring crypto insurance platform Redefind. This strategic move includes the launch of a new digital asset protection service, which will offer comprehensive coverage for asset tracing and legal recovery costs. The acquisition signals WTW's commitment to adapting its services to the evolving digital economy and addressing the growing need for security and recovery solutions within the cryptocurrency market. Investors may view this as a positive step towards diversification and capturing new revenue streams in a burgeoning sector.
via Markets Gazette